Table 2.

Summary of adverse events

Cohorts 1–4 (n = 12)Cohort 5 (n = 3)Cohort 6 (n = 12)Cohort 7 (n = 6)Total (N = 33)
Adverse eventGrade 1–2Grade 3Grade 1–2Grade 3Grade 1–2Grade 3Grade 1–2Grade 3Grade 1–2Grade 3
Frequent drug-related adverse events
  Nausea0000202040
  Chills0010602090
  Fever10209051181
  aPTT prolonged0000300030
  ALT increased0000003030
  AST increased0000103040
  Anorexia0010200030
  Dizziness0010002030
  Hyperhidrosis0000300030
Cohorts 1–4 (n = 12)Cohort 5 (n = 3)Cohort 6 (n = 12)Cohort 7 (n = 6)Total (n = 33)
AllRelatedAllRelatedAllRelatedAllRelatedAllRelated
All grade 3–4 adverse events
  Abdominal pain/cramping0000101020
  Asthenia0000100010
  Disease progression1000000010
  Fatigue2000000020
  Pyrexia0000001111
  LFT increase0000100010
  Hyperbilirubinemia0000100010
  Anemia1000000010
  Hemoglobin decreased1000000010
  Hyperglycemia0000100000
  Electrolyte disorders5000100060
  Spinal cord compression0000001010
  Suicidal ideation0000100010

NOTE: All events occurring in 3 or more patients and all grade 3–4 events.

Abbreviation: LFT, liver function test.